Audits and investigations into the effects of ObamaCare from congressional committees, government auditors, advocacy groups, and others.
“Regulations are slowly strangling HSAs. Under Obamacare, “fully insured” policies must spend at least 80 percent (small group and individual market) or 85 percent (large group market) of every premium dollar on health care related expenses (called the medical loss ratio or MLR). The remainder can be spent on administrative costs (improving health care delivery or combating fraud) and profits.”
“ObamaCare has been a war over the processing of insurance claims. It has been fought by institutional interests representing insurance, hospital and pharmaceutical firms. The doctor-patient relationship, or what used to be called ‘the practice of medicine,’ has sunk beneath these waves.”
“When the Supreme Court upheld the Affordable Care Act in a 5-4 ruling Thursday, the American Medical Association was quick to release a statement in support of the ‘historic’ decision that will give more people access to health coverage.
But (and there’s always a ‘but’) medical professionals across the country are wondering: When an additional 32 million Americans get medical insurance, who exactly is going to treat them?”
“The Affordable Care Act will expand the reach of government into our personal health-care choices, while exacerbating the problems with our current health-care system. Market forces, if allowed to work properly, are the best means for reducing the growth in health costs, encouraging continued innovation, and ensuring that consumers have access to quality health care.”
“IPAB’s unelected members will have effectively unfettered power to impose taxes and ration care for all Americans, whether the government pays their medical bills or not. In some circumstances, just one political party or even one individual would have full command of IPAB’s lawmaking powers. IPAB truly is independent, but in the worst sense of the word. It wields power independent of Congress, independent of the president, independent of the judiciary, and independent of the will of the people.”
“Reviewing peer-reviewed literature on the relationship between medical technology and improvements in life expectancies, Zycher estimates that the knock-on effect of the tax will be about one million life-years lost annually. (Due to limitations in applying the literature, it not possible to tell the degree to which this tilts towards one million people dying one year earlier, or a smaller number of people dying many years earlier. My own interpretation leans towards the latter.)”
“States and the federal government will have to work hard to make sure that new insurance exchanges in President Obama’s healthcare law actually create more competition, a new study says… The Health Affairs study says people in those areas generally pay higher out-of-pocket costs than people in more populated areas with greater competition. ‘If experience with the federal benefits program is an indication of how much competition can be expected in the exchanges, then people obtaining coverage from exchanges will not benefit much from competition unless the exchanges are at least modestly assertive in setting conditions of participation for qualifying health plans,’ the authors wrote.”
“Some colleges are dropping student health-insurance plans for the coming academic year and others are telling students to expect sharp premium increases because of a provision in the federal health law requiring plans to beef up coverage. The demise of low-cost, low-benefit health plans for students is a consequence of the 2010 health-care overhaul.”
“Medical specialists are urging regulators to slow implementation of an initiative funded by the 2010 healthcare law that aims to streamline care for some low-income elderly and disabled patients. “
“This case thus illustrates a serious danger latent in the “comparative effectiveness research” approach taken by the Patient Protection and Affordable Care Act: mass studies of how different treatments affect large swaths of people are not likely to pick up the subtleties and nuances in treatment effectiveness that can vary from person to person based on a whole range factors that determine each individual’s unique biochemistry.”